$PGNX #2 Progenics (PGNX) stock soared 148% while
Post# of 2218
(Total Views: 204)
Posted On: 04/20/2017 3:08:03 PM
$PGNX #2 Progenics (PGNX) stock soared 148% while Gilead (GILD) stock fell 24%.
https://order.investorplace.com/?sid=A6C537&en=4822379
The difference?
Progenics saw its sales jump 3,757% in the third quarter of 2016 compared to the prior year, while Gilead’s sales fell 6% in 2016.
Not to beat up on Gilead, but you can see that same battle for customers and profits at hand when comparing Tenet Healthcare Corp (THC) and Hospital Corporation of America (HCA).
Over the past 12 months, Tenet Healthcare saw its stock collapse 19% while Hospital Corporation of American saw its fortunes rise 30%.
Profit Taker No. 2
When the FDA speeds up drug approvals, it will be hard to beat our best-in-class pharmaceutical company. They have 24 products in Phase III testing that could generate hundreds of millions of dollars in annual sales upon approval.
If these products are just a tenth as successful as the company’s miracle cancer drug, you could see this company’s stock price double annually.
That’s just half the reason you’re going to want to own this one.
This company’s catalog of prescription products reads like a “who’s who” of the most widely prescribed vaccines and medicines in the world to treat conditions such as heart disease, respiratory disease, cancer, and women’s health issues.
As a result, this company not only generates $35 billion a year but also has handed investors annual average gains of 13.9% over the past 47 years. With 9% gains in January, the stock is clearly on its way to lead investors to another successful year.
Profit Taker No. 3
monster biopharmaceutical company is going to thrive under the new health care plan—just as it has for more than 75 years.
In fact, had your parents or grandparents bought you $1,000 worth of shares in 1942, it would be worth more than $206,000 today, not including dividends.
That comes to an annual average gain of 14.15%. And those gains take into account the 12 recessions the U.S. has seen since 1945.
The secret to this company’s long-term success?
The same three factors that will determine health care winners when Obamacare is repealed and replaced: fat profit margins, lower operating costs, and a never-ending pipeline of new medicines.
company produces medicines that treat the conditions many Americans suffer from, including heart disease, cancer, and pain. The demand for these medicines has helped make this company nearly recession-proof.
It's how this company has grown to become a major cash generator with a market value of nearly $200 million and $53 billion in annual sales, netting $14 billion in cash flow—sufficient to pay investors a rich dividend of nearly 4%.
So it’s no wonder the analysts love this one—even in the face of this uncertainty—with five top analysts raising their expectations for 2017.
With 90 drugs in their pipeline, and the Trump administration pushing for faster approvals, you couldn’t ask for a better time to own it. The result will add millions—if not billions—to this company’s coffers for decades to come.
https://order.investorplace.com/?sid=A6C537&en=4822379
The difference?
Progenics saw its sales jump 3,757% in the third quarter of 2016 compared to the prior year, while Gilead’s sales fell 6% in 2016.
Not to beat up on Gilead, but you can see that same battle for customers and profits at hand when comparing Tenet Healthcare Corp (THC) and Hospital Corporation of America (HCA).
Over the past 12 months, Tenet Healthcare saw its stock collapse 19% while Hospital Corporation of American saw its fortunes rise 30%.
Profit Taker No. 2
When the FDA speeds up drug approvals, it will be hard to beat our best-in-class pharmaceutical company. They have 24 products in Phase III testing that could generate hundreds of millions of dollars in annual sales upon approval.
If these products are just a tenth as successful as the company’s miracle cancer drug, you could see this company’s stock price double annually.
That’s just half the reason you’re going to want to own this one.
This company’s catalog of prescription products reads like a “who’s who” of the most widely prescribed vaccines and medicines in the world to treat conditions such as heart disease, respiratory disease, cancer, and women’s health issues.
As a result, this company not only generates $35 billion a year but also has handed investors annual average gains of 13.9% over the past 47 years. With 9% gains in January, the stock is clearly on its way to lead investors to another successful year.
Profit Taker No. 3
monster biopharmaceutical company is going to thrive under the new health care plan—just as it has for more than 75 years.
In fact, had your parents or grandparents bought you $1,000 worth of shares in 1942, it would be worth more than $206,000 today, not including dividends.
That comes to an annual average gain of 14.15%. And those gains take into account the 12 recessions the U.S. has seen since 1945.
The secret to this company’s long-term success?
The same three factors that will determine health care winners when Obamacare is repealed and replaced: fat profit margins, lower operating costs, and a never-ending pipeline of new medicines.
company produces medicines that treat the conditions many Americans suffer from, including heart disease, cancer, and pain. The demand for these medicines has helped make this company nearly recession-proof.
It's how this company has grown to become a major cash generator with a market value of nearly $200 million and $53 billion in annual sales, netting $14 billion in cash flow—sufficient to pay investors a rich dividend of nearly 4%.
So it’s no wonder the analysts love this one—even in the face of this uncertainty—with five top analysts raising their expectations for 2017.
With 90 drugs in their pipeline, and the Trump administration pushing for faster approvals, you couldn’t ask for a better time to own it. The result will add millions—if not billions—to this company’s coffers for decades to come.
(0)
(0)